Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions

British Journal of Clinical Pharmacology

Volumn 48, Issue 6, 1999, Pages 839-846

  Naldi, Luigi ^a   Conforti, Anita ^c   Venegoni, Mauro ^b   Troncon, Maria Grazia ^c   Caputi, Achille ^d   Ghiotto, Elisabetta ^c   Cocci, Alfredo ^e   Moretti, Ugo ^c   Velo, Giampaolo ^c   Leone, Roberto ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c Azienda Sanitaria Locale ^*

^d UNIVERSITY OF MESSINA   (Italy)

^e Azienda Sanitaria Locale   (Italy)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Adverse drug reaction; Skin; Spontaneous reporting

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTACID AGENT; ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIGOUT AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTITUSSIVE AGENT; ANTIULCER AGENT; ANTIVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; CEPHALOSPORIN DERIVATIVE; CONTRAST MEDIUM; COTRIMOXAZOLE; DIPYRONE; DIURETIC AGENT; DOMPERIDONE; FOSINOPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMIPRIL; RENIN INHIBITOR; SCOPOLAMINE BROMIDE; SPASMOLYTIC AGENT; UNINDEXED DRUG; VACCINE;

ADOLESCENT; ADULT; AGED; AGING; ANGIONEUROTIC EDEMA; ARTICLE; CHILD; DRUG SURVEILLANCE PROGRAM; DRUG USE; ERYTHEMA MULTIFORME; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; SEX RATIO; SKIN MANIFESTATION; WORLD HEALTH ORGANIZATION;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG ERUPTIONS; DRUG UTILIZATION; FEMALE; HUMANS; ITALY; MALE; POPULATION SURVEILLANCE;

EID: 0032786871     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00096.x     Document Type: Article

References (49)

1. 1 Olsson S. The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety efforts. Drug Safety 1998; 19: 1-10.
2. 2 McNamee D. Communicating drug-safety information. Lancet 1997; 350: 1646.
3. 3 National pharmacovigilance systems. Country profiles and overview, ed S Olsson. Uppsala: WHO Monitoring Centre, 1997.
4. 4 Roujeau JC, Stern RS. Severe cutaneous adverse reactions to drugs. N Engl J Med 1994; 331: 1272-1285.
5. 5 Stem RS. Identifying adverse reactions to drugs. Reporting systems. Clin Dermatol 1986; 4: 15-22.
6. 6 Ibanez L, Laporte JR, Came X. Adverse drug reactions leading to hospital admission. Drug Safety 1991; 6: 450-459.
7. 7 Conforti A, Leone R, Moretti U, Guglielmo L, Velo GP. Spontaneous reporting of adverse drug reactions in an Italian Region: six years of analysis and observations. Pharmacoepidemiol Drug Safety 1995; 4: 129-135.
8. 8 Bem JL, Mann RD, Rawlins MD. CSM update. Review of yellow cards - 1986 and 1987. Br Med J 1988; 296: 1319.
9. 9 Ochsenfahrt H, Meyer zur Heyde M. Spontaneous Reports Unwanted Drug Effects Years 1978-79. Fortschr Med 1981; 99: 1753-1758.
10. 10 Moore N, Noblet C, Kreft-Jais C, Lagier G, Ollangnier M, Imbs JL. French pharmacovigilance database system. Examples and utilisation. Therapie 1995; 50: 557-562.
11. 11 Figueras A, Capella D, Castel JM, Laporte JR. Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. A report from the Spanish System of Pharmacovigilance, including an early analysis of topical and enteric-coated formulations. Eur J Clin Pharmacol 1994; 47: 297-303.
12. 12 Faich GA, Knapp D, Dreis M, Turner W. National adverse drug reaction surveillance. 1985. JAMA 1987; 257: 2068-2070.
13. 13 Zurcher K, Krebs A. Cutaneous Drug Reactions An Integral Synopsis of Today's Systemic Drugs. Basel: Karger. 1992: 11-23.
14. 14 Naldi L, Locati F, Marchesi L, Cainelli T. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol 1990; 126: 1103.
15. 15 Kelly J, Auquier A, Rzany B, et al. An international collaborative case-control study of severe cutaneous adverse reactions (SCAR): design and methods. J Clin Epidemiol 1995; 48: 1099-1108.
16. 16 Griffin JP, Weber P. Voluntary systems of adverse reactions reporting. Adv Drug React Ac Pois Rev 1985; 3: 161-175.
17. 17 Bigby M, Jick S, Jick H, Arndt KA. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15, 438 consecutive inpatients, 1975-82. JAMA 1986; 256: 3358-3363.
18. 18 Hunziker T, Kunzi UP, Braunschweig S, Zehnder D, Hoigne R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52: 388-393.
19. 19 van der Linden PD, van der Lei J, Vlug AE, Stricker BHCh. Skin reactions to antimicrobial agents in general practice. J Clin Epidemiol 1998; 51: 703-708.
20. 20 Chosidow O, Bourgauh I, Roujeau JC. Drug rashes. What are the targets of cell-mediated toxicity? Arch Dermatol 1994; 130: 627-629.
21. 21 Roujeau JC, Kelly JP, Naldi L, et al. Medication use and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-1607.
22. 22 Lemozit JP, De Rhodiere GP, Lapeyre-Mestre M, Bagheri H, Montastruc JL. A comparative study of adverse drug reactions reported through hospital and private medicine. Br J Clin Pharmacol 1996; 41: 166-168.
23. 23 Shapiro S, Siskind V, Slone D, Lewis GP, Jick H. Drag rash with ampicillin and other penicillins. Lancet 1969; ii: 969-972.
24. 24 Carbonin P, Pahor M, Bernabei R, Sgadari A. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 1991; 39: 1093-1099.
25. 25 Pahor M, Guralnik JM, Gambassi G, Bernabei R, Carosella L, Carbonin P. The impact of age on risk of adverse drug reactions to digoxin. Gruppo Italiano di Farmacovigilanza nell'Anziano. J Clin Epidemiol 1993; 46: 1305-1314.
26. 26 Pahor M, Manto A, Pedonc C, Carosella L, Guralnik JM, Carbonin P. Age and severe adverse drug reactions caused by nifedipine and verapamil. Gruppo Italiano di Farmacovigilanza nell'Anziano.J Clin Epidemiol 1996; 49: 921-928.
27. 27 Gruppo Italiano Studi Epidemiologici in Dermatologia. Cutaneous reactions to analgesic-antipyretics and nonsteroidal anti-inflammatory drugs. Analysis of reports to the spontaneous reporting system of the Gruppo Italiano Studi Epidemiologici in Dermatologia. Dermatology 1993; 186: 164-169.
28. 28 Classen DC, Pestonik SL, Evans S, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991; 266: 2847-2851.
29. 29 Nazareth I, Mortimer P, Kendrick GD. Ampicillin sensitivity in infectious mononucleosis: temporary or permanent? Scan J Infect Dis 1972; 4: 229-230.
30. 30 van der Ven Koopmans PP, Vree TB, van der Meer JWM. Adverse reactions to co-trimoxazole in HIV infection. Lancet 1991; 338: 431-433.
31. 31 Battegay M, Opravil M, Wuthrich B, Luthy R. Rash with amoxicilin-clavulanate therapy in HIV-infected patients. Lancet 1989; ii: 1100.
32. 32 Meyboom RHB, Egberts ACG, Edwards IR, Hekster YA, de Koning FHP, Grignau FWJ. Principles of signal detection in pharmacovigilance. Drug Safety 1997; 6: 355-365.
33. 33 Lietman PS. Fluoroquinolone toxicities. An update. Drugs 1995; 49(Suppl 2): 159-163.
34. 34 Scheife RT, Cramer WR, Decker DL. Photosensitizing potential of ofloxacin. Int J Dermatol 1993; 32: 413-416.
35. 35 Wagai N, Yamaguchi F, Sekiguchi M, Tawara K. Phototoxic potential of quinolone antibacterial agents in Balb/c mice. Toxicol Lett 1990; 54: 299-300.
36. 36 Klimberg IWS, Cox CE, Fowler CL, King W, Kim SS, Callery-D'Amico S. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. Urology 1998; 51: 610-615.
37. 37 Lowe NJ, Fakouhi TD, Stern RS, Bourget T, Roniker B, Swabb EA. Photoreactions with a fluoroquinolone antimicrobial: evening versus morning dosing. Clin Pharmacol Ther 1994; 56: 587-591.
38. 38 Kennard CD. Urticaria. In Conn's Current Therapy 1998, ed Rakel RE. Philadelphia: W.B. Saunders Company, 1998: 850-852.
39. 39 Boston Collaborative Drug Surveillance Program. Dipyrone as a cause of drug rashes: an epidemiologic study. Int J Epidemiol 1973; 2: 167-170.
40. 40 Stern RS, Digby M. An expanded profile of cutaneous reactions to nonsteroidal anti-inflammatory drugs. Reports to a speciality-based system for spontaneous reporting of adverse reactions to drugs. JAMA 1984; 252: 1433-1437.
41. 41 Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-97.
42. 42 Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995; 131: 539-543.
43. 43 Garattini S, Garattini L. Pharmaceutical prescriptions in four European countries. Lancet 1993; 342: 1191-1192.
44. 44 Andersen M, Schou JS. Adverse reactions to H2-receptor antagonists in Denmark before and after transfer of cimetidine and ranitidine to over-the-counter status. Pharmacol Toxicol 1991; 69: 253-258.
45. 45 Gruppo Italiano Studi Epidemiologici in Dermatologia. Cutaneous reactions to alimentary tract medications. Results of a seven-year surveillance program and review of the literature. Dermatology 1996; 193: 11-16.
46. 46 Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988; 260: 967-970.
47. 47 Sabroe RA, Kobza Black A. Angiotensin-coverting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 1997; 136: 153-158.
48. 48 Stern RS, Khalsa JH. Cutaneous adverse reactions associated with calcium channel blockers. Arch Intern Med 1989; 149: 829-832.
49. 49 The Erice Declaration on communicating drug safety information. Prescrire Int 1998; 7: 191.